Seres Therapeutics (MCRB) Misses Q3 EPS by 11c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
November 9, 2020 7:00 AM ESTReported ECOSPOR III Phase 3 study of SER-109 met primary endpoint, demonstrated statistically significant absolute reduction of 30.2% in rate of C. difficile infection recurrence compared to placebo
SER-109 anticipated to be first-ever FDA-approved microbiome therapy
First patient dosed in SER-301 Phase 1b study in mild-to-moderate ulcerative colitis
Strengthened balance sheet with $264 million financing to support R&D and CMC capabilities expansion, ongoing clinical studies, and pre-commercial launch activities
Conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS... More
